May 15 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer that has returned or has not responded to prior treatments. (Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.12 USD | +2.17% | -0.28% | -19.85% |
May. 30 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
May. 30 | Bristol Myers: FDA approval for Breyanzi | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.85% | 83.29B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- US FDA approves expanded use of Bristol's cancer cell therapy